Neuren Pharmaceuticals [ASX: NEU] has raised over $2 million in a share purchase plan [SPP], falling well short of expectations.

The company managed to secure buyers for only 7.3 million of the roughly 25 million shares on offer, totalling just over $580,000.

The SPP had been underwritten by Taylor Collision, which will buy up the remaining 18.2 million shares for $1.46 million.

Struggling biotech Norwood Abbey[ASX: NAL] has received a small cash injection from an unnamed investor.

In return for the $250,000 cash advance, but pending shareholder approval, the investor will receive an option to convert the value of the cash into shares.

This brings the total funds the investor has contributed to $500,000.

Sydney’s NuSep lost over $5 million this financial year but saw decent revenues, unusual in a biotech company in its first year of operation. NuSep earned $1.7 million in revenue over the financial year, with the company's gels business doing well. It has now decided to offload this asset to an undisclosed party to concentrate on its equipment business.

Anadis [ASX: ANX] had to dig deep into its coffers this year to help fund the transition away from manufacturing and towards international operations.

The company lost around $2.6 million for the year, despite selling the health product manufacturing arm of the business in February.

On the plus side, the company's net loss was significantly lower than last year's results of $3.28 million.

Newcomer Incitive [ASX: ICV] posted a modest loss this year, as the fledgling company made progress developing products based on its lead compound.

The company posted a loss of $2.25 million for the financial year, more than double the loss accumulated last year.

But Incivite's consolidated loss for the year was only $1.6 million, significantly less than half of the losses accrued last year.

The pre-adjusted losses were balanced out in part by an injection of funds through capital-raising share placement schemes.

Biosensor company Ambri [ASX: ABI] has obtained shareholder approval to change its name to Diversa.

The name change has been approved by the Australian Securities and Investments Commission [ASIC] and will take effect on Thursday, when it will begin trading with the ASX code of DVA.